Humatrix, a medical technology company in SIP, recently announced to launch the multi-center clinical trial (MCCT) of its LineMatrix? at over 10 hospitals across the country. LineMatrix? is the first domestically developed bioartificial blood vessel.
Founded in 2021, Humatrix is dedicated to developing tissue engineering and regenerative medicine products. It is the only company in China and the second in the world to have been able to make small-diameter artificial blood vessels.
The LineMatrix? bioartificial blood vessel surpasses similar foreign products with its low immunogenicity and anti-calcification design. Compared with traditional products made of high polymer materials, it demonstrates superior advantages including endothelialization capacity, higher patency rates, infection resistance, and puncture durability. These features significantly reduce postoperative interventions and lower both healthcare system expenditures and patients’ medical expenses.
June 24, 2025
